Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in
Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in those markets to build defensible, strong, and long-term businesses.build portfolio among attractive life science sectors in a manner that balances risk while maximizing potential synergies and ultimate returns. Our focus is on opportunities in biotechnology, medical devices, and diagnostics, but we are continually responsive to the best areas for investing in order to adapt to changing market conditions.Invest in companies that: * are pursuing substantial and growing market opportunities * possess a unique and proprietary technology, with a clear competitive advantage * are early-stage opportunities * have or will attract strong management * have a strong investment syndicate * offer a defined path to liquidity
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 11, 2022
Neumora Therapeutics
|
Series B | $112M | Biotechnology | — |
Apr 19, 2022
Tessera Therapeutics
|
Series C | $300M | Biopharma | — |
Nov 18, 2021
Generate Biomedicines
|
Series B | $370M | Biotechnology | — |
Oct 7, 2021
Neumora Therapeutics
|
Series A | $400M | Biotechnology | — |
Jan 12, 2021
Tessera Therapeutics
|
Series B | $230M | Biopharma | — |